Pharmacotherapeutic Options for Visceral Leishmaniasis—Current Scenario
Clinical medicine. Pathology · 2009
DOI: 10.4137/cpath.s821 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical medicine. Pathology, 2009. Verfasst von Krishna Pandey und 5 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 19 Literaturangaben.
Abstract (Originalsprache)
Visceral leishmaniasis (VL) or Kala-azar is a protozoal disease, which was previously regarded as one of the most neglected tropical diseases. Management of this disease is quite difficult, because it is said to affect the poorest of the poor. Previously Sodium Stibogluconate (SSG) was regarded as the gold standard treatment for VL. But due to the increasing unresponsiveness, to this drug various other drugs were tried and are still being tried. Pentamidine is very toxic and has been discarded of late. Amphotericin B and its lipid formulations are very effective but require hospital admission and monitoring. Oral drugs like Miltefosine have already been launched. An amino glycoside Paromomycin and another oral drug Sitamaquine are in the pipe line. Interferon gamma has been used with discouraging results.
Zitieren
APA
Pandey, K., Sinha, P. K., Das, V. R., Bimal, S., Singh, S. K., & Das, P. (2009). Pharmacotherapeutic Options for Visceral Leishmaniasis—Current Scenario. Clinical medicine. Pathology. https://doi.org/10.4137/cpath.s821
Vancouver
Pandey K, Sinha PK, Das VR, Bimal S, Singh SK, Das P. Pharmacotherapeutic Options for Visceral Leishmaniasis—Current Scenario. Clinical medicine. Pathology. 2009. doi:10.4137/cpath.s821
BibTeX
@article{Pandey2009,
author = {Pandey, Krishna and Sinha, Prabhat Kumar and Das, Vidyanand Ravi and Bimal, Sanjiva and Singh, Shubhankar K. and Das, Pradeep},
title = {Pharmacotherapeutic Options for Visceral Leishmaniasis—Current Scenario},
journal = {Clinical medicine. Pathology},
year = {2009},
doi = {10.4137/cpath.s821}
}
EUVIMED